David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images)
April 27, 2023 03:24 PM EDTUpdated 04:45 PM
Pharma

Eli Lil­ly will use a pri­or­i­ty re­view vouch­er on Moun­jaro to 're­move any un­cer­tain­ty' around fast FDA re­view

Nicole DeFeudis

Editor

Eli Lil­ly isn’t wait­ing around for the FDA’s fast-track path­way. The team is “fever­ish­ly” sub­mit­ting its new Phase III da­ta for Moun­jaro in obe­si­ty, and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

A service from the Financial Times